

1 Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 2 subvariant

3

4 Khadija Khan^{1,2}, Gila Lustig³, Kajal Reedoy¹, Zesuliwe Jule¹, Cornelius Römer^{4,5}, Farina
5 Karim^{1,2}, Yashica Ganga¹, Mallory Bernstein¹, Zainab Baig¹, Boitshoko Mahlangu⁶, Anele
6 Mnguni⁶, Ayanda Nzimande⁶, Nadine Stock⁶, Dikeledi Kekana⁶, Buhle Ntozini⁶, Cindy van
7 Deventer⁷, Terry Marshall⁷, Nithendra Manickchand⁸, Bernadett I. Gosnell⁸, Richard J.
8 Lessells^{3,9}, Quarraisha Abdool Karim^{3,10}, Salim S. Abdool Karim^{3,10}, Mahomed-Yunus S.
9 Moosa⁸, Tulio de Oliveira^{3,9,11,12}, Anne von Gottberg^{6,13}, Nicole Wolter^{6,13}, Richard A Neher^{4,5},
10 Alex Sigal^{1,2,3}

11 ¹Africa Health Research Institute, Durban, South Africa. ²School of Laboratory Medicine and Medical
12 Sciences, University of KwaZulu-Natal, Durban, South Africa. ³Centre for the AIDS Programme of
13 Research in South Africa, Durban, South Africa. ⁴Biozentrum, University of Basel, Basel, Switzerland.
14 ⁵Swiss Institute of Bioinformatics, Lausanne, Switzerland. ⁶Centre for Respiratory Diseases and
15 Meningitis, National Institute for Communicable Diseases, a division of the National Health Laboratory
16 Service, Johannesburg, South Africa. ⁷Ampath Molecular Biology, Centurion, South Africa. ⁸Department
17 of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal,
18 Durban, South Africa. ⁹KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South
19 Africa. ¹⁰Department of Epidemiology, Mailman School of Public Health, Columbia University, New
20 York, USA. ¹¹Centre for Epidemic Response and Innovation, School of Data Science and Computational
21 Thinking, Stellenbosch University, Stellenbosch, South Africa. ¹²Department of Global Health,
22 University of Washington, Seattle, USA. ¹³School of Pathology, University of the Witwatersrand,
23 Johannesburg, South Africa.

24

25 **Omicron BA.2.86 subvariant differs from Omicron BA.2 as well as recently circulating**
26 **variants by over 30 mutations in the spike protein alone. Here we report on the first**
27 **isolation of the live BA.2.86 subvariant from a diagnostic swab collected in South Africa**
28 **which we tested for escape from neutralizing antibodies and viral replication properties**
29 **in cell culture. BA.2.86 did not have significantly more escape than Omicron XBB.1.5**
30 **from neutralizing immunity elicited by infection of Omicron subvariants ranging from**
31 **BA.1 to XBB, either by infection alone or as breakthrough infection in vaccinated**
32 **individuals. Neutralization escape was present relative to earlier strains: BA.2.86**
33 **showed extensive escape both relative to ancestral virus in sera from pre-Omicron**
34 **vaccinated individuals and relative to Omicron BA.1 in sera from Omicron BA.1 infected**
35 **individuals. We did not observe substantial differences in viral properties in cell culture**
36 **relative to XBB.1.5. Both BA.2.86 and XBB.1.5 produced infection foci of similar size,**
37 **had similar cytopathic effect (both lower than ancestral SARS-CoV-2), and had similar**
38 **replication dynamics. We also investigated the relationship of BA.2.86 to BA.2**
39 **sequences and found that the closest were BA.2 samples from Southern Africa**
40 **circulating in early 2022. These observations suggest that BA.2.86 is more closely**
41 **related to sequences from Southern Africa than other regions and so may have evolved**
42 **there, and that evolution led to escape from neutralizing antibodies similar in scale to**
43 **recently circulating strains of SARS-CoV-2.**

44 The Omicron subvariant BA.2.86 is derived from the BA.2 subvariant but has over 30
45 mutations in spike relative to both BA.2 and recently circulating subvariants such as XBB.1.5
46 (Fig 1A), making its emergence a major concern since many of the mutations are predicted to
47 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. confer escape from neutralizing antibodies (1). Levels of neutralizing antibodies have been

48 found to strongly correlate with protection from symptomatic infection with SARS-CoV-2 (2).
49 SARS-CoV-2 variant mutations occurring in the receptor binding domain and N terminal
50 domain of spike tend to reduce the ability of antibodies elicited by previous infection or
51 vaccination to neutralize SARS-CoV-2 (3-6), although protection from more severe disease
52 may be partly maintained by conserved T cell responses (7).

53 The Omicron BA.2.86 subvariant started to be identified by global genomic surveillance
54 samples collected from 24 July 2023 onwards, but because of the reduced rate of surveillance
55 the exact time when it started to spread is unclear. Likewise, it is unclear when and where it
56 arose. BA.2.86 shares the synonymous mutation C26681T and the spike substitution S939F
57 with BA.2 genomes sampled in South Africa in early 2022, while it lacks the mutation C9866T
58 that is present in the great majority of BA.2 sequences sampled outside of Southern Africa
59 (Fig 1B). Southern African sequences are also closely related to the putative ancestral
60 sequence of BA.2.86. Of the 10 branches that emanate from the basal polytomy within
61 BA.2.86, 8 are dominated by samples from Southern Africa (Fig 1B). Most sequences from
62 the Northern Hemisphere fall into a second large polytomy designated as BA.2.86.1,
63 separated from the basal polytomy by two mutations. Available BA.2.86 sequences differ from
64 their most recent common ancestor (MRCA) by 1-7 mutations. Most samples were collected
65 mid-August and have 3-5 mutations relative to the MRCA. SARS-CoV-2 accumulates about
66 15 mutations per year along acute transmission chains and we thus estimate that this
67 subvariant started to spread about May 2023 (8). The estimate is corroborated by molecular
68 clock analysis with TreeTime, which suggests an emergence date in early May with an
69 uncertainty of about two months (Fig 1B).

70 The virus tested here is from a nasopharyngeal swab sample collected in Mpumalanga
71 Province, South Africa on July 28, 2023 (Fig 1B, arrow). Sequence results were released on
72 August 22, 2023 (GISAID accession GISAID accession EPI_ISL_18125249). Outgrowth to
73 expand this virus was started on August 24, 2023, in the Vero-TMPRSS cell line, where two
74 passages were performed (Materials and Methods). The sequence of the outgrown virus was
75 deposited on GISAID (EPI_ISL_18226980) with no clear in-vitro sequence changes detected
76 relative to the accepted Omicron BA.2.86 sequence.

77 Because the pressing concern is that BA.2.86 can escape current population immunity, we
78 compared neutralization of BA.2.86 to XBB.1.5 using sera from individuals who were
79 vaccinated and had breakthrough infection with an Omicron subvariant (Fig 1C, see Table S1
80 for participant details), or infected with an Omicron subvariant only (Fig 1D, see Table S2 for
81 participant details). We found that there was no significant escape relative to XBB.1.5 in either
82 of these groups. The exceptions were two unvaccinated participants who were infected during
83 the XBB dominant period who did show substantial BA.2.86 escape relative to XBB.1.5 (Fig
84 1D and Table S2). However, it is difficult to determine if this is part of a pattern since we could
85 not enroll more unvaccinated XBB subvariant or later subvariant infected participants. Some
86 of the participants were people living with HIV (PLWH). In all except for one case HIV was
87 suppressed with effective antiretroviral therapy. HIV status did not noticeably change the
88 similar neutralization of XBB.1.5 and BA.2.86 (Fig S1).

89 Next, we examined if this variant evolved escape to neutralizing immunity relative to earlier
90 SARS-CoV-2 strains. We checked neutralization of vaccinated individual sera collected pre-
91 Omicron which we previously used to determine escape of the original Omicron BA.1
92 subvariant (3). Here, we found over 100-fold escape of BA.2.86 relative to ancestral SARS-
93 CoV-2, 5-fold greater than observed for BA.1 (Fig 1E). We also tested for escape relative to

94 Omicron BA.1 in people infected with BA.1. Here we again found extensive escape, 14-fold
95 relative to BA.1. However, XBB.1.5 showed a similar, 12-fold escape (Fig 1F).

96 We then investigated whether there were any differences in focus formation - the number of
97 cells infected by a single cell which formed an infected cell cluster. This is a measure of cell-
98 to-cell spread of the virus (9). We also measured cytopathic effect and viral replication. We
99 found that both BA.2.86 and XBB.1.5 made infection foci which were 5-fold and 4.5-fold
100 smaller in area relative to those made by ancestral SARS-CoV-2 at 20 hours post-infection
101 (Fig 2A, quantitation in Fig 2B). The same viral inoculum led to considerable cytopathic (CPE)
102 effect by 72 hours in ancestral SARS-CoV-2 infected cells. Similar number of infection foci led
103 to substantially less CPE at the same timepoint in both BA.2.86 and XBB.1.5 infections (Fig
104 2A). We also could not detect substantial differences in replication in cell culture between
105 BA.2.86 and XBB.1.5 (Fig 2C).

106 These results indicate that, although the Omicron BA.2.86 subvariant has evolved extensive
107 escape from neutralizing antibodies, it is recognized by convalescent plasma to a similar
108 degree as the XBB.1.5 subvariant. This similarity in recognition might explain the
109 comparatively slow spread of the variant relative to the spread of BA.1 or BA.2 in 2021. These
110 observations are similar to data reported over the past week showing limited or no escape of
111 BA.2.86 relative to current circulating variants (10-12). Unlike the first study to report (11), we
112 did not obtain data consistent with lower cellular infectivity of BA.2.86 relative to XBB.1.5,
113 although this may be because of the different cellular assays used. A limitation of our data is
114 that it is based on a single BA.2.86 isolate.

115 Our analysis suggests that BA.2.86 descends from viruses that circulated in early 2022 without
116 any observed intermediates and only started to spread recently. There may be several
117 explanations for the long period of evolution in the absence of population spread, including
118 evolution in long-term SARS-CoV-2 infection during immunosuppression due to factors such
119 as advanced HIV disease (13-15) as well as infection in an animal reservoir (15, 16).

120 While BA.2.86 may lead to new infections in the population, our data does not indicate that it
121 is very different than SARS-CoV-2 strains already in circulation.

122

123

124 **Methods**

125 Informed consent and ethical statement

126 Blood samples and nasopharyngeal swab for ancestral D614G SARS-CoV-2 isolation were
127 obtained after written informed consent from adults with PCR-confirmed SARS-CoV-2
128 infection who were enrolled in a prospective cohort study at the Africa Health Research
129 Institute approved by the Biomedical Research Ethics Committee at the University of
130 KwaZulu-Natal (reference BREC/00001275/2020). The Omicron/BA.1 and BA.2.86 was
131 isolated from a residual swab sample with SARS-CoV-2 isolation from the sample approved
132 by the University of the Witwatersrand Human Research Ethics Committee (HREC) (ref.
133 M210752). The sample to isolate XBB.1.5 was collected after written informed consent as part
134 of the COVID-19 transmission and natural history in KwaZulu-Natal, South Africa:
135 Epidemiological Investigation to Guide Prevention and Clinical Care in the Centre for the AIDS
136 Programme of Research in South Africa (CAPRISA) study and approved by the Biomedical

137 Research Ethics Committee at the University of KwaZulu–Natal (reference
138 BREC/00001195/2020, BREC/00003106/2021).

139

140

141 Reagent availability statement

142 Viral isolates are available upon reasonable request. Sequences of isolated SARS-CoV-2
143 used in this study have been deposited in GISAID with accession numbers as follows:

| Virus | GISAID |
|----------------|------------------|
| D614G | EPI_ISL_602626.1 |
| XBB.1.5 | EPI_ISL_17506815 |
| BA.2.86 | EPI_ISL_18226980 |
| BA.1 | EPI_ISL_7886688 |

144

145 Sequences used in phylogenetic analysis: GISAID Identifier: EPI_SET_230907xn, doi:
146 10.55876/gis8.230907xn. All genome sequences and associated metadata in this dataset
147 are published in GISAID's EpiCoV database. To view the contributors of each individual
148 sequence with details such as accession number, Virus name, Collection date, Originating
149 Lab and Submitting Lab and the list of Authors, see 10.55876/gis8.230907xn

150 Data Snapshot: EPI_SET_230907xn is composed of 347 individual genome sequences. The
151 collection dates range from 2021-12-14 to 2023-08-30; Data were collected in 42 countries
152 and territories; All sequences in this dataset are compared relative to hCoV-
153 19/Wuhan/WIV04/2019 (WIV04), the official reference sequence employed by GISAID
154 (EPI_ISL_402124). For more information see at <https://gisaid.org/WIV04>.

155 Whole-genome sequencing and genome assembly

156 For the BA.2.86 swab sample, RNA was extracted on an automated Chemagic 360
157 instrument, using the CMG-1049 kit (Perkin Elmer, Hamburg, Germany). Libraries for whole
158 genome sequencing were prepared using the Illumina COVIDseq Assay (Illumina Inc, San
159 Diego, CA) and version 4 SARS-CoV-2 primer pools. Pooled PCR products were fragmented
160 and tagged to adapter sequences. The adapter-tagged amplicons were purified and indexed
161 using sets 1-4 of PCR indexes (Illumina). Libraries were quantified using a Qubit 4.0
162 fluorometer (ThermoFisher Scientific, Oregon, USA) using the Qubit dsDNA High Sensitivity
163 assay according to the manufacturer's instructions. Fragment sizes were analyzed using the
164 TapeStation 4200 system (Agilent Technologies, Santa Clara, CA). Libraries were pooled and
165 normalized to 4nM sample library with 2% PhiX spike-in. Libraries were loaded onto a 300-
166 cycle NextSeq P2 Reagent Kit v2 and run on the Illumina NextSeq 1000/2000 instrument
167 (Illumina). Sequencing data was analyzed using Exatype v4.1.5 (Hyra Biosciences, Cape
168 Town, South Africa) with default parameters (10% minimum prevalence to report variants,
169 80% minimum prevalence to include a variant in consensus sequence). Nextclade (v2.14.1)
170 and Pangolin (v4.3, Pangolin-data v1.21) were used for clade and lineage assignments.
171 Additionally Nextclade was used for visualization of the sequences and the identification of

172 frameshifts. Unknown frameshifts were manually corrected using Aliview (v1.24).
173 Outbreak.info was used to determine the prevalence of mutations.

174 For the BA.2.86 outgrowth sample, Oxford Nanopore sequencing was performed. RNA was
175 manually extracted from either 200uL input volume using either the MagMAX™
176 Viral/Pathogen II Nucleic Acid Isolation Kit (Thermo Scientific) or from 140uL using the
177 QIAamp Viral RNA Kit (Qiagen) as per the manufacturer's protocols. All RNA extractions were
178 measured using Qubit fluorimeter kits (Thermo Scientific). The cDNA synthesis was performed
179 using LunaScript RT mastermix (New England BioLabs) followed by whole-genome multiplex
180 PCR using the Midnight Primer pools v3 (EXP-MRT001, Oxford Nanopore) that produce
181 1,200-base-pair amplicons. The amplified products for each pool were combined and used to
182 library preparation procedures using Oxford Nanopore Rapid Barcoding kit (SQK-RBK110.96,
183 Oxford Nanopore). The barcoded samples were pooled and cleaned-up using magnetic beads
184 and loaded on an R9.4.1 flow cell for 8-hours sequencing on a MinION device. The raw data
185 was processed using Guppy basecaller and Guppy barcoder (Oxford Nanopore) for
186 basecalling and demultiplexing. The final consensus sequences were obtained using the
187 Genome Detective v2.64. The lineage assignment was determined using Nextclade.

188 Phylogenetic analysis

189 We assembled a set of 280 BA.2 (Nextstrain clade 21L) sequences collected between
190 November 2021 and June 2022 from data deposited on GISAID (17). BA.2.86 sequences
191 were downloaded on September 7 2023 directly from GISAID. We excluded sequences with
192 reversion mutations relative to BA.2, sequences flagged as poor quality by Nextclade (18), or
193 sequences with less than 90% coverage of the reference. Sequences were pairwise aligned
194 against Wuhan-Hu-1 using Nextclade. Terminals and gaps were masked as well as all
195 suspected artefactual reversions to reference in BA.2.86 sequences. A tree was built using
196 IQ-tree 2 (19) and postprocessed using a custom script to correct for incomplete merging of
197 branches in large polytomies.

198 A time tree was inferred using TreeTime (20) using a clock rate of 0.0005 per site and year
199 [Neher 2022]. The rate of the long branch between BA.2 and BA.2.86 was set to be 2 times
200 the rate of the rest of the tree in line with previous observation that evolution is 2-fold
201 accelerated along many long branches leading to distinct clades [Neher (2022)]. This
202 acceleration is consistent with the dramatic enrichment of amino acid substitutions in the spike
203 protein along the long branch leading to BA.2.86.

204 The phylogenetic workflow is available at github.com/neherlab/BA286. The repository
205 contains a specific list of sites (config/mask.tsv) that are masked in individual sequences.

206 An interactive version of the phylogenetic tree is available at

207 <https://nextstrain.org/groups/neherlab/ncov/BA.2.86>

208 Cells

209 The VeroE6 cells expressing TMPRSS2 and ACE2 (VeroE6-TMPRSS2), originally BEI
210 Resources, NR-54970 were used for virus expansion and all live virus assays excluding
211 replication. The Vero-TMPRSS2 cell line was propagated in growth medium consisting of
212 Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum (Hyclone) containing
213 10mM of hydroxyethylpiperazine ethanesulfonic acid (HEPES), 1mM sodium pyruvate, 2mM
214 L-glutamine and 0.1mM nonessential amino acids (Sigma-Aldrich). The H1299-E3 (H1299-
215 ACE2, clone E3) cell line used in the replication assay was derived from H1299 (CRL-5803)
216 and propagated in growth medium consisting of complete Roswell Park Memorial Institute

217 (RPMI) 1640 with 10% fetal bovine serum containing 10mM of HEPES, 1mM sodium pyruvate,
218 2mM L-glutamine and 0.1mM nonessential amino acids.

219

220

221 Virus expansion

222 All work with live virus was performed in Biosafety Level 3 containment using protocols for
223 SARS-CoV-2 approved by the Africa Health Research Institute Biosafety Committee. VeroE6-
224 TMRSS2 cells were seeded at 4.5×10^5 cells in a 6 well plate well and incubated for 18–20
225 hours pre-infection. After one Dulbecco's phosphate-buffered saline (DPBS) wash, the sub-
226 confluent cell monolayer was inoculated with 500 μ L with universal transport medium which
227 contained the swab, diluted 1:2 with growth medium filtered through a 0.45 μ m and 0.22 μ m
228 filters. Cells were incubated for 2 hours. Wells were then filled with 3 mL complete growth
229 medium. After 3 days of infection (completion of passage 1 (P1)), supernatant was collected,
230 cells were trypsinized, centrifuged at 300 rcf for 3 min and resuspended in 3mL growth
231 medium. All infected cells and supernatant were added to VeroE6-TMRSS2 cells that had
232 been seeded at 1.5×10^5 cells per mL, 20mL total, 18–20 hour earlier in a T75 flask for cell-
233 to-cell infection. The coculture was incubated for 1 h and the flask was filled with 20mL of
234 complete growth medium and incubated for 3 days. The viral supernatant from this culture
235 (passage 2 (P2) stock) was used for experiments.

236 Live virus focus forming assay and neutralization assay

237 VeroE6-TMRSS2 cells were plated in a 96-well plate (Corning) at 30,000 cells per well 1 day
238 pre-infection. Plasma was separated from EDTA-anticoagulated blood by centrifugation at 500
239 rcf for 10 min and stored at -80°C . Aliquots of plasma samples were heat-inactivated at 56°C
240 for 30 min and clarified by centrifugation at 10,000 rcf for 5 min. Virus stocks were used at
241 approximately 50-100 focus-forming units per microwell and added to diluted plasma in
242 neutralization assays. Antibody–virus mixtures were incubated for 1 h at 37°C , 5% CO_2 . Cells
243 were infected with 100 μ L of the virus–antibody mixtures for 1 h, then 100 μ L of a 1X RPMI
244 1640 (Sigma-Aldrich, R6504), 1.5% carboxymethylcellulose (Sigma-Aldrich, C4888) overlay
245 was added without removing the inoculum. Cells were fixed 20 h post-infection using 4% PFA
246 (Sigma-Aldrich) for 20 min. Foci were stained with a rabbit anti-spike monoclonal antibody
247 (BS-R2B12, GenScript A02058) at 0.5 μ g/mL in a permeabilization buffer containing 0.1%
248 saponin (Sigma-Aldrich), 0.1% BSA (Sigma-Aldrich) and 0.05% Tween-20 (Sigma-Aldrich) in
249 PBS. Plates were incubated with primary antibody for 2 h at room temperature with shaking,
250 then washed with wash buffer containing 0.05% Tween-20 in PBS. Secondary goat anti-rabbit
251 HRP conjugated antibody (Abcam ab205718) was added at 1 μ g/mL and incubated for 2 h at
252 room temperature with shaking. TrueBlue peroxidase substrate (SeraCare 5510-0030) was
253 then added at 50 μ L per well and incubated for 20 min at room temperature. Plates were
254 imaged in an ImmunoSpot Ultra-V S6-02-6140 Analyzer ELISPOT instrument with BioSpot
255 Professional built-in image analysis (C.T.L) which was also used to quantify areas of individual
256 foci.

257 Plaque Assay

258 VeroE6-TMRSS2 cells were plated in a 96-well plate (Corning) at 30,000 cells per well 1 day
259 pre-infection. Virus stocks were used at the focus-forming units per microwell shown in Figure
260 2 and added cells, incubated for 1 h at 37°C , 5% CO_2 . Following incubation, 100 μ L of a 1X
261 RPMI 1640 (Sigma-Aldrich, R6504), 1.5% carboxymethylcellulose (Sigma-Aldrich, C4888)
262 overlay was added without removing the inoculum. Cells were fixed 72 hours post-infection

263 using 4% PFA (Sigma-Aldrich) for 20 min. The fixed cells were washed with distilled water and
264 stained with 30 μ L/well of a 0.5% crystal violet solution (Sigma-Aldrich, 61135).

265 Cycle threshold values for SARS-CoV-2 RNA copies

266 SARS-CoV-2 cycle threshold (Ct) quantification was performed from sample supernatant at
267 an accredited diagnostic laboratory (Molecular Diagnostic Services, Durban, South Africa).
268 Samples were extracted using a guanidine isothiocyanate/ magnetic bead based method with
269 the NucliSense (Biomerieux) extractor of the KingFisher Flex 96 (Thermo Fisher). RT-qPCR
270 was performed using the Seegene Allplex 2019 nCoV assay with the Bio-Rad CFX96 real-
271 time PCR instrument as per the kit instructions. RNase P is used as the internal housekeeping
272 gene to monitor extraction and assay efficiency. The kit targets the E, N and R genes of SAR
273 CoV-2. Run calls and interpretation is performed by the Seegene Viewer software. Fold-
274 change was calculated as $FC = 2^{((\text{mean}(Ct \text{ input}) - Ct \text{ sample}))}$

275 Statistics and fitting

276 All statistics and fitting were performed using custom code in MATLAB v.2019b. Neutralization
277 data were fit to:

$$278 \quad T_x = 1 / (1 + (D / ID_{50})) \quad (1)$$

279 Here T_x is the number of foci at plasma dilution D normalized to the number of foci in the
280 absence of plasma on the same plate. ID_{50} is the plasma dilution giving 50% neutralization.
281 $FRNT_{50} = 1 / ID_{50}$. Values of $FRNT_{50} < 1$ are set to 1 (undiluted), the lowest measurable value.
282 We note that the most concentrated plasma dilution was 1:25 and therefore $FRNT_{50} < 25$ were
283 extrapolated.

284

285 Acknowledgements

286 This study was supported by the Bill and Melinda Gates award INV-018944, Wellcome Trust
287 Award 226137/Z/22/Z, University of Washington Arboviral Research Network (UWARN)
288 Subaward #UWSC14272 and the South African Medical Research Council to AS. We thank
289 the originating and submitting labs of the SARS-CoV-2 sequences used in this study for timely
290 sharing of their data (EPI_SET_230907xn). We particularly thank Amos Adler and his team
291 and the Danish COVID-19 Genomics Consortium, whose surveillance efforts have led to the
292 detection of BA.2.86. We thank github user Silcn and Andrew Rambaut for discussions of
293 phylogenetic aspects and sequence quality.

294 Competing interest statement

295 The authors declare no competing interests.

296

297

298

299 References

300

- 301 1. Dadonaite B, Crawford KHD, Radford CE, Farrell AG, Yu TC, Hannon WW, et al. A pseudovirus
302 system enables deep mutational scanning of the full SARS-CoV-2 spike. *Cell*. 2023;186(6):1263-
303 78.e20.
- 304 2. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
305 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
306 *Nature medicine*. 2021:1-7.
- 307 3. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron extensively
308 but incompletely escapes Pfizer BNT162b2 neutralization. *Nature*. 2021.
- 309 4. Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, et al. Omicron BA.4/BA.5 escape
310 neutralizing immunity elicited by BA.1 infection. *Nat Commun*. 2022;13(1):4686.
- 311 5. McCallum M, De Marco A, Lempp FA, Tortorici MA, Pinto D, Walls AC, et al. N-terminal
312 domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. *Cell*. 2021;184(9):2332-47
313 e16.
- 314 6. Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, et al. SARS-CoV-2
315 neutralizing antibody structures inform therapeutic strategies. *Nature*. 2020;588(7839):682-7.
- 316 7. Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, et al. T cell responses to
317 SARS-CoV-2 spike cross-recognize Omicron. *Nature*. 2022.
- 318 8. Neher RA. Contributions of adaptation and purifying selection to SARS-CoV-2 evolution.
319 *Virus Evolution*. 2022;8(2).
- 320 9. Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, et al. Altered
321 TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. *Nature*. 2022.
- 322 10. Sheward DJ, Yang Y, Westerberg M, Öling S, Muschiol S, Sato K, et al. Sensitivity of BA.2.86
323 to prevailing neutralising antibody responses. *bioRxiv*. 2023:2023.09.02.556033.
- 324 11. Yang S, Yu Y, Jian F, Song W, Yisimayi A, Chen X, et al. Antigenicity and infectivity
325 characterization of SARS-CoV-2 BA.2.86. *bioRxiv*. 2023:2023.09.01.555815.
- 326 12. Lasrado N, Collier A-r, Hachmann N, Miller J, Rowe M, Schonberg E, et al. Neutralization
327 Escape by SARS-CoV-2 Omicron Subvariant BA.2.86. *bioRxiv*. 2023:2023.09.04.556272.
- 328 13. Karim F, Bernstein M, Jule Z, Lustig G, Upton J-L, Ganga Y, et al. Emergence of neutralizing
329 antibodies associates with clearance of SARS-CoV-2 during HIV-mediated immunosuppression.
330 *medRxiv*. 2023:2023.08.18.23293746.
- 331 14. Cele S, Karim F, Lustig G, San JE, Hermanus T, Tegally H, et al. SARS-CoV-2 prolonged
332 infection during advanced HIV disease evolves extensive immune escape. *Cell Host & Microbe*. 2022.
- 333 15. Peacock TP, Penrice-Randal R, Hiscox JA, Barclay WS. SARS-CoV-2 one year on: evidence for
334 ongoing viral adaptation. *The Journal of General Virology*. 2021;102(4).
- 335 16. Hoffmann M, Zhang L, Krüger N, Graichen L, Kleine-Weber H, Hofmann-Winkler H, et al.
336 SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. *Cell Rep*.
337 2021;35(3):109017.
- 338 17. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to
339 reality. *Euro Surveill*. 2017;22(13).
- 340 18. Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment, mutation
341 calling and quality control for viral genomes. *Journal of open source software*. 2021;6(67):3773.
- 342 19. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-
343 TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. *Mol Biol*
344 *Evol*. 2020;37(5):1530-4.
- 345 20. Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic analysis.
346 *Virus Evol*. 2018;4(1):vex042.

347

348 **Figure Legends**

349 **Figure 1: BA.2.86 evolution and neutralization escape.** (A) Changes relative to Omicron
350 XBB.1.5 and BA.2. (B) Phylogenetic analysis. BA.2.86 sequences form a distinct cluster
351 separated from BA.2 sequences circulating late 2021/early 2022 by a long branch labeled
352 BA.2.86. Outgrown sample marked by arrow. The BA.2.86 branch connects to samples with
353 the mutations C26681T and C24378T (Spike: S939F) but lacks C9866T present in most
354 BA.2 sequences. (C) Neutralization of BA.2.86 live virus versus XBB.1.5 by sera from
355 vaccinated individuals with breakthrough BA.1/BA.4/BA.5/XBB family subvariant infection.
356 Numbers above columns are group geometric mean titer FRNT₅₀ and fold-change. (D)
357 BA.2.86 versus XBB.1.5 neutralization by sera from unvaccinated individuals infected with
358 Omicron BA.1/BA.4/BA.5/XBB family subvariants. (E) Neutralization of BA.2.86 versus
359 ancestral D614G and BA.1 viruses by sera from vaccinated individuals collected before
360 Omicron emergence. (F) Neutralization of BA.2.86 versus Omicron BA.1 by sera from
361 vaccinated and unvaccinated BA.1 infected individuals. Significant p-values were
362 ****p<0.0001, **p=0.0042 by the Wilcoxon Rank Sum test.

363 **Figure 2: Omicron BA.2.86 replication and spread in cell culture.** (A) Foci formed by
364 ancestral D614G, XBB.1.5, and BA.2.86 at 20 hours post-infection on Vero-TMPRSS2 cells
365 (rows 1, 3, 5) and cytopathic effect formed by the same viral inoculum on Vero-TMPRSS2 at
366 72 hours post-infection (rows 2, 4, 6). Rows 1 and 2 were infected with ancestral SARS-
367 CoV-2, 3 and 4 with XBB.1.5, and 5 and 6 with BA.2.86. Foci number per well is indicated
368 above each well. Bar is 2mm. (B) Quantitation of focus area for D614G, XBB.1.5, and
369 BA.2.86. Significant p-values were ****p<0.0001 by the Wilcoxon Rank Sum test. (C) Fold-
370 change in SARS-CoV-2 viral copies as determined using qPCR cycle threshold over 4 days
371 of infection in H1299-ACE2 cells.

372 **Figure S1: Neutralization escape of Omicron BA.2.86 relative to XBB.1.5 by HIV status.**
373 (A) Neutralization of XBB.1.5 and BA.2.86 in vaccinated individuals with breakthrough
374 Omicron variant infection. Y-axis is neutralization as FRNT₅₀ and numbers above each
375 column are geometric mean titer (GMT) FRNT₅₀ for the group. Sera from people living with
376 HIV (PLWH) are on the left panel and HIV negative participants on the right. (B)
377 Neutralization of XBB.1.5 and BA.2.86 in unvaccinated individuals infected with Omicron
378 subvariants.

379




Figure 1: BA.2.86 evolution and neutralization escape. (A) Changes relative to Omicron XBB.1.5 and BA.2. (B) Phylogenetic analysis. BA.2.86 sequences form a distinct cluster separated from BA.2 sequences circulating late 2021/early 2022 by a long branch labeled BA.2.86. Outgroup sample marked by arrow. The BA.2.86 branch connects to samples with the mutations C26681T and C24378T (Spike: S939F) but lacks C9866T present in most BA.2 sequences. (C) Neutralization of BA.2.86 live virus versus XBB.1.5 by sera from vaccinated individuals with breakthrough BA.1/BA.4/BA.5/XBB family subvariant infection. Numbers above columns are group geometric mean titer $FRNT_{50}$ and fold-change. (D) BA.2.86 versus XBB.1.5 neutralization by sera from unvaccinated individuals infected with Omicron BA.1/BA.4/BA.5/XBB family subvariants. (E) Neutralization of BA.2.86 versus ancestral D614G and BA.1 viruses by sera from vaccinated individuals collected before Omicron emergence. (F) Neutralization of BA.2.86 versus Omicron BA.1 by sera from vaccinated and unvaccinated BA.1 infected individuals. Significant p-values were ****p<0.0001, **p=0.0042 by the Wilcoxon Rank Sum test.




Figure 2: Omicron BA.2.86 replication and spread in cell culture. (A) Foci formed by ancestral D614G, XBB.1.5, and BA.2.86 at 20 hours post-infection on Vero-TMPRSS2 cells (rows 1, 3, 5) and cytopathic effect formed by the same viral inoculum on Vero-TMPRSS2 at 72 hours post-infection (rows 2, 4, 6). Rows 1 and 2 were infected with ancestral SARS-CoV-2, 3 and 4 with XBB.1.5, and 5 and 6 with BA.2.86. Foci number per well is indicated above each well. Bar is 2mm. (B) Quantitation of focus area for D614G, XBB.1.5, and BA.2.86. Significant p-values were ****p<0.0001 by the Wilcoxon Rank Sum test. (C) Fold-change in SARS-CoV-2 viral copies as determined using qPCR cycle threshold over 4 days of infection in H1299-ACE2 cells.




Figure S1: Neutralization escape of Omicron BA.2.86 relative to XBB.1.5 by HIV status.
 A) Neutralization of XBB.1.5 and BA.2.86 in vaccinated individuals with breakthrough Omicron variant infection. Y-axis is neutralization as $FRNT_{50}$ and numbers above each column are geometric mean titer (GMT) $FRNT_{50}$ for the group. Sera from people living with HIV (PLWH) are on the left panel and HIV negative participants on the right. (B) Neutralization of XBB.1.5 and BA.2.86 in unvaccinated individuals infected with Omicron subvariants.

Table S1: Vaccinated with Omicron BTI participants

| | Sex | Age range | Sample collected (date) | Infecting variant# | Infection (date) | Vacc type | Last Vacc (date) | Infection to sample (date)* | HIV status | BA.1 FRNT50 | XBB.1.5 FRNT50 | BA.2.86 FRNT50 |
|----|-----|-----------|-------------------------|--------------------|------------------|-------------|------------------|-----------------------------|------------|-------------|----------------|----------------|
| 1 | M | 50-59 | Jan 22 | BA.1 | Dec 21 | BNT162b2 | Aug 21 | 17 | + | 1335.8 | 256.4 | 186.0 |
| 2 | M | 30-39 | Dec 21 | BA.1 | Dec 21 | Ad26.COVS.S | Mar 21 | 23 | - | 731.7 | 42.6 | 41.5 |
| 3 | M | 30-39 | Dec 21 | BA.1 | Nov 21 | Ad26.COVS.S | May 21 | 21 | - | 1282.7 | 17.0 | 12.5 |
| 4 | F | 50-59 | Dec 21 | BA.1 | Dec 21 | BNT162b2 | Jul 21 | 23 | + | 756.3 | 62.7 | 24.0 |
| 5 | F | 30-39 | Jan 22 | BA.1 | Dec 21 | Ad26.COVS.S | Apr 21 | 22 | + | 899.2 | 177.5 | 168.5 |
| 6 | F | 60-69 | Jan 22 | BA.1 | Dec 21 | BNT162b2 | Jul 21 | 24 | - | 1221.8 | 83.6 | 52.8 |
| 7 | F | 50-59 | Jan 22 | BA.1 | Dec 21 | Ad26.COVS.S | Jul 21 | 23 | + | 522.3 | 82.9 | 49.4 |
| 8 | M | 30-39 | Dec 21 | BA.1 | Dec 21 | BNT162b2 | Jul 21 | 27 | - | 486.5 | 17.2 | 14.6 |
| 9 | F | 30-39 | Jan 22 | BA.1 | Dec 21 | Ad26.COVS.S | Aug 21 | 21 | - | 619.0 | 34.6 | 12.3 |
| 10 | F | 80-89 | Jan 22 | BA.1 | Jan 22 | BNT162b2 | Jul 21 | 22 | - | 1210.8 | 468.8 | 169.7 |
| 11 | M | 60-69 | Jan 22 | BA.1 | Dec 21 | BNT162b2 | Jul 21 | 24 | - | 264.5 | 84.1 | 70.0 |
| 12 | F | 40-49 | May 22 | BA.5 | Apr 22 | BNT162b2 | Aug 21 | 34 | + | N/A | 46.8 | 49.1 |
| 13 | M | 40-49 | May 22 | BA.5 | May 22 | Ad26.COVS.S | Feb 21 | 29 | - | N/A | 188.0 | 190.2 |
| 14 | M | 50-59 | Aug 22 | BA.5 | Jul 22 | BNT162b2 | Nov 21 | 29 | - | N/A | 342.5 | 269.3 |
| 15 | F | 70-79 | May 22 | BA.5 | N/A | BNT162b2 | Jul 21 | N/A | - | N/A | 75.7 | 156.0 |
| 16 | M | 70-79 | May 22 | BA.5 | N/A | BNT162b2 | Jul 21 | N/A | - | N/A | 1.4 | 5.1 |
| 17 | F | 40-49 | Jul 22 | BA.5 | N/A | Ad26.COVS.S | Mar 21 | N/A | - | N/A | 24.1 | 47.1 |
| 18 | F | 30-39 | Feb 23 | BA.5 | Jan 23 | BNT162b2 | Oct 21 | 35 | + | N/A | 11.1 | 7.6 |
| 19 | F | 30-39 | Mar 23 | BA.5 | Feb 23 | BNT162b2 | Jan 22 | 29 | + | N/A | 168.2 | 245.7 |
| 20 | M | 30-39 | Mar 23 | BA.5 | Feb 23 | BNT162b2 | Jun 21 | 30 | - | N/A | 233.7 | 50.2 |
| 21 | M | 40-49 | Jun 22 | BA.5 | May 22 | BNT162b2 | Sep 21 | 36 | + | N/A | 799.2 | 413.8 |
| 22 | F | 20-29 | May 23 | XBB | N/A | Ad26.COVS.S | Mar 21 | N/A | - | N/A | 1126.8 | 764.3 |
| 23 | F | 30-39 | May 23 | XBB | Apr 23 | BNT162b2 | Jul 21 | 14 | - | N/A | 629.2 | 349.5 |
| 24 | F | 50-59 | Jun 23 | XBB | May 23 | BNT162b2 | Sep 21 | 29 | - | N/A | 924.3 | 628.6 |
| 25 | F | 60-69 | May 23 | XBB | May 23 | BNT162b2 | Jul 21 | 13 | + | N/A | 504.6 | 404.4 |
| 26 | F | 70-79 | May 23 | XBB | N/A | BNT162b2 | Nov 21 | N/A | - | N/A | 3262.3 | 2175.3 |
| 27 | M | 40-49 | Jun 23 | XBB | N/A | Ad26.COVS.S | Nov 21 | N/A | - | N/A | 948.2 | 353.7 |
| 28 | F | 40-49 | May 23 | XBB | N/A | Ad26.COVS.S | May 21 | N/A | + | N/A | 113.2 | 110.1 |
| 29 | M | 70-79 | Oct 22 | XBB | Oct 22 | BNT162b2 | Aug 21 | 14 | - | N/A | 2522.4 | 1273.2 |

#Determined by infection date. *Infection date is by date of diagnostic swab.

Table S2: Unvaccinated with Omicron infection participants

| | Sex | Age range | Sample collected (date) | Infecting Variant# | Infection Date* | Infection to sample (date) | HIV status | BA.1 FRNT50 | XBB.1.5 FRNT50 | BA.2.86 FRNT50 |
|------|-----|-----------|-------------------------|--------------------|-----------------|----------------------------|------------|-------------|----------------|----------------|
| 1 | F | 30-39 | Jan 22 | BA.1 | Dec 21 | 23 | + | 7963.06 | 187.34 | 207.40 |
| 2 | F | 20-29 | Dec 21 | BA.1 | Dec 21 | 21 | - | 540.03 | 36.06 | 68.98 |
| 3 | F | 20-29 | Dec 21 | BA.1 | Dec 21 | 21 | - | 345.02 | 45.90 | 54.60 |
| 4 | F | 50-59 | Jan 22 | BA.1 | Dec 21 | 31 | + | 290.00 | 76.89 | 64.08 |
| 5 | F | 60-69 | Jan 22 | BA.1 | Dec 21 | 17 | - | 826.48 | 34.08 | 66.15 |
| 6 | F | 50-59 | Jan 22 | BA.1 | Dec 21 | 27 | + | 316.99 | 25.57 | 39.76 |
| 7 | F | 50-59 | Jan 22 | BA.1 | Dec 21 | 21 | - | 1046.76 | 49.91 | 30.38 |
| 8 | F | 50-59 | Jan 22 | BA.1 | Dec 21 | 31 | + | 2001.21 | 157.74 | 133.82 |
| 9 | F | 30-39 | May 22 | BA.5 | Mar 22 | 78 | + | N/A | 17.9 | 24.6 |
| 10 | M | 40-49 | Jun 22 | BA.5 | May 22 | 35 | + | N/A | 384.2 | 558.9 |
| 11 | F | 50-59 | Aug 22 | BA.5 | Jul 22 | 30 | - | N/A | 30.5 | 18.3 |
| 12 | M | 60-69 | Aug 22 | BA.5 | Jul 22 | 27 | - | N/A | 254.3 | 203.7 |
| 13 | F | 40-49 | Feb 23 | BA.5 | Jan 23 | 33 | - | N/A | 275.5 | 134.0 |
| 14** | F | 30-39 | Mar 23 | BA.5 | Mar 23 | 17 | + | N/A | 2003.2 | 1769.6 |
| 15 | M | 50-59 | May 23 | XBB | N/A | N/A | - | N/A | 10239.0 | 1735.9 |
| 16 | M | 60-69 | Apr 23 | XBB | Apr 23 | 28 | - | N/A | 955.9 | 39.2 |

#Determined by infection date. *Infection date is by date of diagnostic swab. **Viremic. HIV viral load = 2383 copies/mL.

Table S3: BNT162b2 Vaccinated pre-Omicron participants

| | Sex | Age range | Sample collected (date) | Last Vacc. (date) | Vacc. to sample (days) | HIV status | D614G FRNT50 | BA.1 FRNT50 | BA.2.86 FRNT50 |
|-----------|-----|-----------|-------------------------|-------------------|------------------------|------------|--------------|-------------|----------------|
| 1 | F | 40-49 | Sep 21 | Aug 21 | 32 | + | 942.3 | 10.9 | 9.6 |
| 2 | F | 40-49 | Oct 21 | Sep 21 | 34 | + | 16919.6 | 984.1 | 76.0 |
| 3 | F | 60-69 | Oct 21 | Aug 21 | 63 | - | 11788.5 | 621.0 | 68.1 |
| 4 | M | 40-49 | Oct 21 | Oct 21 | 18 | + | 9629.4 | 749.5 | 36.7 |
| 5 | M | 70-79 | Aug 21 | Jun 21 | 38 | - | 5025.0 | 137.8 | 35.6 |
| 6 | F | 60-69 | Jul 21 | Jul 21 | 11 | - | 301.1 | 16.0 | 9.9 |
| 7 | M | 70-79 | Jul 21 | Jul 21 | 11 | - | 720.2 | 45.3 | 8.8 |
| 8 | M | 30-39 | Aug 21 | Jul 21 | 15 | + | 893.5 | 44.2 | 9.7 |
| 9 | F | 70-79 | Jul 21 | Jul 21 | 10 | - | 300.5 | 24.2 | 17.3 |
| 10 | F | 30-39 | Jul 21 | Jul 21 | 11 | + | 2002.2 | 75.8 | 16.2 |
| 11 | F | 20-29 | Nov 21 | Oct 21 | 31 | - | 3625.0 | 234.5 | 13.3 |
| 12 | M | 20-29 | Nov 21 | Oct 21 | 30 | - | 2963.4 | 104.0 | 27.7 |
| 13 | F | 60-69 | Aug 21 | Jul 21 | 28 | - | 59258.6 | 1143.2 | 74.3 |
| 14 | M | 60-69 | Aug 21 | Jul 21 | 26 | - | 71412.3 | 2779.6 | 117.2 |
| 15 | F | 40-49 | Nov 21 | Oct 21 | 33 | + | 15276.3 | 1104.9 | 327.6 |
| 16 | M | 50-59 | Oct 21 | Sep 21 | 30 | - | 21376.2 | 759.2 | 72.7 |
| 17 | F | 50-59 | Nov 21 | Oct 21 | 13 | - | 2915.2 | 385.3 | 90.7 |
| 18 | F | 60-69 | Nov 21 | Nov 21 | 14 | + | 12699.9 | 174.2 | 117.7 |
| 19 | F | 30-39 | Aug 21 | Jul 21 | 34 | + | 258.6 | 4.6 | 5.4 |